Using multiple primary endpoints in clinical trials with a focus on heart failure

Published: June 28, 2024
Abstract Views: 3809
PDF: 443
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The use of multiple primary endpoints in cardiovascular clinical trials could be useful addition to the arsenal of comprehensive evaluations of meaningful clinical outcomes. Particularly, it may be advantageous and more economic to use several primary endpoints, if several useful endpoint alternatives exist and when it is uncertain what degree of benefit a certain intervention to be tested can achieve, i.e. what power a trial has for a given endpoint. However, analysis of multiple endpoints gives rise to issues of multiplicity of outcomes and family-wise error rate. There are statistical adjustment models (single and multistep) that modify the level of significance for each endpoint based on the number of endpoints considered overall to control the family-wise error rate. The Bonferroni method is a single step approach that divides the nominal significance level alpha equally across all endpoints but is considered a conservative approach in cases where the number of endpoints is large and where endpoints are correlated. The most used multistep approaches include the Holm and Hochberg procedures. The Hochberg method is a more efficient, and less conservative approach towards alpha adjustment compared to the Holm procedure. The Bonferroni, Holm and Hochberg test procedures are all considered suitable analysis strategies for multiple primary endpoints with no need to determine a priori the order for the testing to be performed as is needed in all hierarchical test procedures that are most commonly used today. Furthermore, these strategies can also be used to protect the error rate when including secondary endpoints in an extended analytical procedure. The use of any of these methods needs to be specified a priori in the statistical analysis plan to ensure adequate statistical validity. Examples of clinical trials in the heart failure field that have used or are using such multiple primary endpoint approaches are: MIRACLE, ASCEND-HF, EVEREST, FAIR-HF, DELIVER, RESHAPE-HF2 and FAIR-HF2.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Alosh M. Bretz F, Huque M. Advanced multiplicity adjustment methods in clinical trials. Stat Med 2014;33:693-713. DOI: https://doi.org/10.1002/sim.5974
Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895-904. DOI: https://doi.org/10.1016/S0140-6736(20)32339-4
Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199-209. DOI: https://doi.org/10.1016/S0140-6736(22)02083-9
Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med 2024;390:1455-66. DOI: https://doi.org/10.1056/NEJMoa2314051
Siddiqi TJ, Butler J, Coats AJS, et al. SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials. Global Cardiology 2023;1:2. DOI: https://doi.org/10.4081/globalcard.2023.2
Li G, Taljaard M, Van Den Heuvel ER, et al. An introduction to multiplicity issues in clinical trials: the what, why, when and how. Int J Epidemiol 2017;46:746-56. DOI: https://doi.org/10.1093/ije/dyw320
Crawford J, Prado CMM, Johnston MA, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep 2016;18:37. DOI: https://doi.org/10.1007/s11912-016-0522-0
Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53. DOI: https://doi.org/10.1056/NEJMoa013168
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48. DOI: https://doi.org/10.1056/NEJMoa0908355
Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-91. DOI: https://doi.org/10.1093/eurjhf/hfp140
Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-31. DOI: https://doi.org/10.1001/jama.297.12.1319
O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43. DOI: https://doi.org/10.1056/NEJMx110061
Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98. DOI: https://doi.org/10.1056/NEJMoa2206286
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84. DOI: https://doi.org/10.1056/NEJMc2312296
Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394-407. DOI: https://doi.org/10.1056/NEJMoa2313917
Chen SY, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. J Thorac Dis 2017;9:1725. DOI: https://doi.org/10.21037/jtd.2017.05.34
FDA. Multiple endpoints in clinical trials guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry (accessed March 23, 2024).
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28:586-604. DOI: https://doi.org/10.1002/sim.3495
Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995;310:170. DOI: https://doi.org/10.1136/bmj.310.6973.170
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2. DOI: https://doi.org/10.1093/biomet/75.4.800
Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
Anker SD, Friede T, von Bardeleben RS, et al. Randomized investigation of the MitraClip device in heart failure: design and rationale of the RESHAPE-HF2 trial design. Eur J Heart Fail 2024;26:984-93. DOI: https://doi.org/10.1002/ejhf.3247
Rosano GMC. Clinical trial design, endpoints and regulatory considerations in heart failure. Global Cardiology 2024;2:18 DOI: https://doi.org/10.4081/cardio.2024.18
ClinicalTrials.gov. Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. Available from: https://clinicaltrials.gov/study/NCT03036462 (accessed May 29, 2024).
Rosano GMC, Farkas J. Evolving targets for heart failure: the journey so far. Global Cardiology 2023;1:6. DOI: https://doi.org/10.4081/globalcard.2023.6
Talha KM, Butler J, Haehling S von, et al. Defining iron replete status in patients with heart failure treated with intravenous iron. Global Cardiology 2023;1:17. DOI: https://doi.org/10.4081/cardio.2023.17

How to Cite

Anker, S. D., Butler, J., Talha, K. M., & Friede, T. (2024). Using multiple primary endpoints in clinical trials with a focus on heart failure. Global Cardiology, 2(2). https://doi.org/10.4081/cardio.2024.33

Similar Articles

1 2 3 4 > >> 

You may also start an advanced similarity search for this article.